Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07382960

Pramipexole and the Risk of Serious Adverse Events

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

View on ClinicalTrials.gov

Summary

This is a population-based cohort study assessing whether initiation of a higher dose of pramipexole (0.25 or 0.375 mg/day), compared with a lower dose (0.125 mg/day), in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits, or all-cause mortality.

Official title: Assessing the 30-Day Risk of Adverse Outcomes With Pramipexole Use in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol

Key Details

Gender

All

Age Range

66 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1100

Start Date

2008-01-01

Completion Date

2028-12-31

Last Updated

2026-09-14

Healthy Volunteers

No

Interventions

DRUG

Pramipexole

The primary exposure of interest will be oral pramipexole at a 0.125 mg/day. For the primary comparison, this dose has been selected to reduce the potential influence of indication bias.

Locations (1)

London Health Sciences Centre Research Institute

London, Ontario, Canada